Prostate Cancer News

Greater utilization of genetic testing among men could have considerable benefits with regard to detection, risk management and personalized treatment of cancers, according to authors of a review published in JAMA Oncology.

The addition of six cycles of radium-223 to first-line enzalutamide extended radiographic PFS for men with metastatic castration-resistant prostate cancer, according to results of a randomized phase 3 trial.

National Prostate Cancer Awareness Month is observed every September.

Olaparib monotherapy may be an effective treatment option for certain men with biochemically recurrent prostate cancer, according to results of a nonrandomized phase 2 trial.

Spouses of people with cancer exhibited significantly higher risk for attempted suicide and suicide death than those whose spouses had not been diagnosed with cancer, according to a nationwide cohort study in Denmark.

More than 16% of Americans live at least a 4-hour drive from the closest proton beam therapy facility, according to data published in JAMA Network Open.

The addition of a pre-ketone supplement to an immunotherapy regimen demonstrated efficacy for treating prostate cancer, according to a study led by researchers at University of Notre Dame.

Men with bone pain at diagnosis of metastatic, hormone-resistant prostate cancer had shorter survival than men without bone pain, according to study results.

In this episode, host Shikha Jain, MD, speaks with Shyam Natarajan, PhD, about machine learning in cancer research and testing, using technological innovation to address disparities in health care trials and more.